Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ascenta Therapeutics
Further Study Details provided by Ascenta:
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed small cell lung cancer (SCLC). Mixed histology will not be eligible.
Progression of disease after only one prior platinum containing chemotherapy regimen. Prior Regimen must not have contained irinotecan
All patients must have measurable disease.
Patients may have received prior radiation therapy but they must have recovered from all treatment-related toxicities.
ECOG performance status 0-1
Adequate hematologic function
Adequate liver and renal function
Ability to swallow oral medication
You may not be if
Patients with more than one prior regimen of chemotherapy or prior regimen that did not contain a platinum agent. Note: Patient who stopped prior therapy due to toxicity or had less than 2 cycles of platinum based therapy would not be eligible for the phase II portion of this study.
Prior chemotherapy regimen containing irinotecan.
Active secondary malignancy.
Unstable or progressive brain metastases.
Prior history of radiation therapy to \> 25% of the bone marrow.
Uncontrolled concurrent illness including, but not limited to: serious uncontrolled infection, symptomatic congestive heart failure (CHF), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with the study requirements.
Failure to recover from toxicities related to prior therapy (e.g., surgery, radiation, chemotherapy).
